Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma

Leukemia. 2014 Dec;28(12):2413-5. doi: 10.1038/leu.2014.248. Epub 2014 Aug 25.

Authors

S Z Usmani¹, Q Zhang², K Stratton³, P Qu³, S Yaccoby², E Hansen³, D Steward², S Panozzo², N Petty², A Hoering³, S Waheed², F Van Rhee², J Crowley³, B Barlogie²

Affiliations

¹ 1] Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA [2] Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC, USA.
² Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
³ Cancer Research and Biostatistics, Seattle, WA, USA.

PMID: 25151956
DOI: 10.1038/leu.2014.248

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use*
Humans
Multiple Myeloma / drug therapy*
Multiple Myeloma / mortality
Multiple Myeloma / pathology*
Recurrence
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use
Treatment Outcome

Substances

Antineoplastic Agents
Thalidomide
pomalidomide